Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection

Journal of Virology

Volumn 87, Issue 16, 2013, Pages 8826-8842

  Sukupolvi Petty, Soila ^a   Brien, James D ^a   Austin, S Kyle ^a   Shrestha, Bimmi ^a   Swayne, Sherri ^b   Kahle, Kristen ^b   Doranz, Benjamin J ^b   Johnson, Syd ^c   Pierson, Theodore C ^d   Fremont, Daved H ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Integral Molecular Inc   (United States)

^c Analytical Sciences   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E106 PROTEIN MONOCLONAL ANTIBODY; E119 PROTEIN MONOCLONAL ANTIBODY; E121 PROTEIN MONOCLONAL ANTIBODY; E138 PROTEIN MONOCLONAL ANTIBODY; E27 PROTEIN MONOCLONAL ANTIBODY; E29 PROTEIN MONOCLONAL ANTIBODY; E3 PROTEIN MONOCLONAL ANTIBODY; E33 PROTEIN MONOCLONAL ANTIBODY; E4 PROTEIN MONOCLONAL ANTIBODY; E40 PROTEIN MONOCLONAL ANTIBODY; E60 PROTEIN MONOCLONAL ANTIBODY; E68 PROTEIN MONOCLONAL ANTIBODY; E72 PROTEIN MONOCLONAL ANTIBODY; E75 PROTEIN MONOCLONAL ANTIBODY; E76 PROTEIN MONOCLONAL ANTIBODY; E78 PROTEIN MONOCLONAL ANTIBODY; E86 PROTEIN MONOCLONAL ANTIBODY; E87 PROTEIN MONOCLONAL ANTIBODY; E88 PROTEIN MONOCLONAL ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS PROTECTION; DENGUE; DENGUE VIRUS 4; EPITOPE MAPPING; GENETIC VARIABILITY; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEROTYPE; SINGLE DRUG DOSE; TEMPERATURE SENSITIVITY; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; EPITOPES; MICE; MICE, INBRED C57BL; PROTEIN BINDING; TEMPERATURE; TIME FACTORS; VIRAL ENVELOPE PROTEINS;

EID: 84881224582     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01314-13     Document Type: Article

References (89)

1. Durbin AP, Whitehead SS. 2010. Dengue vaccine candidates in development. Curr. Top. Microbiol. Immunol. 338:129-143.
2. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. 2011. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:7229-7241.
3. Gubler DJ. 2012. The economic burden of dengue. Am. J. Trop. Med. Hyg. 86:743-744.
4. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507.
5. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengasa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567.
6. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
7. Zhang X, Ge P, Yu X, Brannan JM, Bi G, Zhang Q, Schein S, Zhou ZH. 2013. Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat. Struct. Mol. Biol. 20:105-110.
8. Kostyuchenko VA, Zhang Q, Tan JL, Ng TS, Lok SM. 2013. Immature and mature dengue serotype 1 virus structures provide insight into the maturation process. J. Virol. 87:7700-7707.
9. Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, Rossmann MG. 2013. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc. Natl. Acad. Sci. U. S. A. 110:6795-6799.
10. Fibriansah G, Ng TS, Kostyuchenko VA, Lee J, Lee S, Wang J, Lok SM. 2013. Structural changes of dengue virus when exposed to a temperature of 37°C. J. Virol. 87:7585-7592.
11. Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, Baker TS, Strauss JH, Kuhn RJ, Rossmann MG. 2003. Structures of immature flavivirus particles. EMBO J. 22:2604-2613.
12. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH. 2009. Structural basis for the preferential binding of immature flaviviruses by a fusion-loop specific antibody. EMBO 28:3269-3276.
13. Wengler G. 1989. Cell-associated West Nile flavivirus is covered with E + pre-M protein heterodimers which are destroyed and reorganized by proteolytic cleavage during virus release. J. Virol. 63:2521-2526.
14. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319:1830-1834.
15. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319:1834- 1837.
16. Yu IM, Holdaway HA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J. 2009. Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion. J. Virol. 83:12101-12107.
17. Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 100:6986-6991.
18. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319.
19. Modis Y, Ogata S, Clements D, Harrison SC. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79:1223-1231.
20. Nayak V, Dessau M, Kucera K, Anthony K, Ledizet M, Modis Y. 2009. Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J. Virol. 83: 4338-4344.
21. Mondotte JA, Lozach PY, Amara A, Gamarnik AV. 2007. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J. Virol. 81:7136-7148.
22. Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, Xiao C, Gregorio GG, Hendrickson WA, Kuhn RJ, Rossmann MG. 2006. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124:485-493.
23. Tassaneetrithep B, Burgess T, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller M, Pattanapanyasat K, Sarasombath S, Birx D, Steinman RM, Schlesinger S, Marovich M. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197:823-829.
24. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, Virelizier JL, Arenzana-Seisdedos F, Despres P. 2003. Dendritic-cellspecific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 4:723-728.
25. Bhardwaj S, Holbrook M, Shope RE, Barrett AD, Watowich SJ. 2001. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J. Virol. 75:4002-4007.
26. Volk DE, Beasley DW, Kallick DA, Holbrook MR, Barrett AD, Gorenstein DG. 2004. Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J. Biol. Chem. 279:38755-38761.
27. Yu S, Wuu A, Basu R, Holbrook MR, Barrett AD, Lee JC. 2004. Solution structure and structural dynamics of envelope protein domain III of mosquitoand tick-borne flaviviruses. Biochemistry 43:9168-9176.
28. Rico-Hesse R. 1990. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 174:479-493.
29. Holmes EC, Twiddy SS. 2003. The origin, emergence and evolutionary genetics of dengue virus. Infect. Genet. Evol. 3:19-28.
30. Rossi SL, Nasar F, Cardosa J, Mayer SV, Tesh RB, Hanley KA, Weaver SC, Vasilakis N. 2012. Genetic and phenotypic characterization of sylvatic dengue virus type 4 strains. Virology 423:58-67.
31. Vasilakis N, Fokam EB, Hanson CT, Weinberg E, Sall AA, Whitehead SS, Hanley KA, Weaver SC. 2008. Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains. Virology 377:296-307.
32. Durbin AP, Mayer SV, Rossi SL, Amaya-Larios IY, Ramos-Castaneda J, Eong Ooi E, Jane Cardosa M, Munoz-Jordan JL, Tesh RB, Messer WB, Weaver SC, Vasilakis N. 2013. Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. Virology 439:34-41.
33. Rothman AL. 2004. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113:946-951.
34. Lanciotti RS, Gubler DJ, Trent DW. 1997. Molecular evolution and phylogeny of dengue-4 viruses. J. Gen. Virol. 78:2279-2284.
35. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 6(4):e1000823. doi:10.1371/journal.ppat.1000823.
36. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. 2010. Natural strain variation and antibody neutralization of Dengue serotype 3 viruses. PLoS Pathog. 6(3):e1000821. doi:10.1371 /journal.ppat.1000821.
37. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS. 2010. Genotype specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 84:10630-10643.
38. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84:9227-9239.
39. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. 2007. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5:518-528.
40. Morens DM, Venkateshan CN, Halstead SB. 1987. Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses. J. Gen. Virol. 68:91-98.
41. Yamanaka A, Kosugi S, Konishi E. 2008. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J. Virol. 82:927-937.
42. Men R, Yamashiro T, Goncalvez AP, Wernly C, Schofield DJ, Emerson SU, Purcell RH, Lai CJ. 2004. Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus. J. Virol. 78:4665-4674.
43. Lai CJ, Goncalvez AP, Men R, Wernly C, Donau O, Engle RE, Purcell RH. 2007. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J. Virol. 81:12766-12774.
44. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283.
45. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 80:12149-12159.
46. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6(2):e1000790. doi:10.1371/journal.ppat.1000790.
47. Temporao JG, Penna GO, Carmo EH, Coelho GE, do Socorro Silva Azevedo R, Teixeira Nunes MR, da Costa Vasconcelos PF. 2011. Dengue virus serotype 4, Roraima State, Brazil. Emerg. Infect. Dis. 17:938-940.
48. Vasilakis N, Weaver SC. 2008. The history and evolution of human dengue emergence. Adv. Virus Res. 72:1-76.
49. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken G, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Typeand subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816-12826.
50. Harlow E, Lane D. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
51. Fuchs A, Pinto AK, Schwaeble WJ, Diamond MS. 2011. The lectin pathway of complement activation contributes to protection from West Nile virus infection. Virology 412:101-109.
52. Oliphant T, Engle M, Nybakken G, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
53. Paes C, Ingalls J, Kampani K, Sulli C, Kakkar E, Murray M, Kotelnikov V, Greene TA, Rucker JB, Doranz BJ. 2009. Atomic-level mapping of antibody epitopes on a GPCR. J. Am. Chem. Soc. 131:6952-6954.
54. Johnson AJ, Roehrig JT. 1999. New mouse model for dengue virus vaccine testing. J. Virol. 73:783-786.
55. Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M, Lemon SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS. 2011. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 85:7005-7019.
56. Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, Diamond MS, Harris E. 2013. Therapeutic efficacy of antibodies lacking FcγR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. PLoS Pathog. 9(2):e1003157. doi:10.1371/journal.ppat.1003157.
57. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-317.
58. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7(6):e1002111. doi:10.1371/journal.ppat.1002111.
59. Sabo MC, Luca VC, Ray SC, Bukh J, Fremont DH, Diamond MS. 2012. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology 422:174-184.
60. Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH. 2012. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog. 8(10):e1002930. doi:10.1371/journal.ppat.1002930.
61. Halstead SB, Venkateshan CN, Gentry MK, Larsen LK. 1984. Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J. Immunol. 132:1529-1532.
62. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:10208-10217.
63. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349-360.
64. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828-8837.
65. Matsui K, Gromowski G, Li L, Barrett AD. 2010. Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. J. Gen. Virol. 91:2249-2253.
66. Matsui K, Gromowski GD, Li L, Schuh AJ, Lee JC, Barrett AD. 2009. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384:16-20.
67. Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S. 2013. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J. Virol. 87:52-66.
68. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 5(6):e1188. doi:10.1371/journal.pntd.0001188.
69. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U. S. A. 109:7439-7444.
70. Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS. 2011. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fc-γ receptor and complement-dependent effector mechanisms. J. Virol. 22: 11567-11580.
71. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4(5):e1000060. doi:10.1371/journal.ppat.1000060.
72. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135-145.
73. Halstead SB. 2012. Dengue vaccine development: a 75% solution? Lancet 380:1535-1536.
74. Nybakken G, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 2005. Structural basis for neutralization of a therapeutic antibody against West Nile virus. Nature 437:764-769.
75. Choi KS, Nah JJ, Ko YJ, Kim YJ, Joo YS. 2007. The DE loop of the domain III of the envelope protein appears to be associated with West Nile virus neutralization. Virus Res. 123:216-218.
76. Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG. 2010. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. U. S. A. 107:18950-18955.
77. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4:139ra183.
78. Tan GK, Ng JK, Trasti SL, Schul W, Yip G, Alonso S. 2010. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl. Trop. Dis. 4(4):e672. doi:10.1371 /journal.pntd.000672.
79. Grant D, Tan GK, Qing M, Ng JK, Yip A, Zou G, Xie X, Yuan Z, Schreiber MJ, Schul W, Shi PY, Alonso S. 2011. A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis. J. Virol. 85:7775-7787.
80. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128-139.
81. Agarwal JP, Bhattacharyya PC, Das SK, Sharma M, Gupta M. 2009. Dengue encephalitis. Southeast Asian J. Trop. Med. Public Health 40: 54-55.
82. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G. 2003. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol. Med. Microbiol. 35:33-42.
83. Costa VV, Fagundes CT, Valadao DF, Cisalpino D, Dias AC, Silveira KD, Kangussu LM, Avila TV, Bonfim MR, Bonaventura D, Silva TA, Sousa LP, Rachid MA, Vieira LQ, Menezes GB, de Paula AM, Atrasheuskaya A, Ignatyev G, Teixeira MM, Souza DG. 2012. A model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-gamma in host resistance to infection. PLoS Negl. Trop. Dis. 6(5):e1663. doi:10.1371/journal.pntd.0001663.
84. Souza DG, Fagundes CT, Sousa LP, Amaral FA, Souza RS, Souza AL, Kroon EG, Sachs D, Cunha FQ, Bukin E, Atrasheuskaya A, Ignatyev G, Teixeira MM. 2009. Essential role of platelet-activating factor receptor in the pathogenesis of dengue virus infection. Proc. Natl. Acad. Sci. U. S. A. 106:14138-14143.
85. Yu CY, Chang TH, Liang JJ, Chiang RL, Lee YL, Liao CL, Lin YL. 2012. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog. 8(6):e1002780. doi:10.1371/journal.ppat.1002780.
86. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, Bernal-Rubio D, Shabman RS, Simon V, RodriguezMadoz JR, Mulder LC, Barber GN, Fernandez-Sesma A. 2012. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog. 8(10):e1002934. doi:10.1371/journal.ppat.1002934.
87. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A. 2009. NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 83:5408-5418.
88. Ashour J, Morrison J, Laurent-Rolle M, Belicha-Villanueva A, Plumlee CR, Bernal-Rubio D, Williams KL, Harris E, Fernandez-Sesma A, Schindler C, Garcia-Sastre A. 2010. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 8:410-421.
89. Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA. 2012. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 20:303-314.